MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine

MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidineMTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine, Published online: 05 December 2017; doi:10.1038/tpj.2017.48MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine
Source: The Pharmacogenomics Journal - Category: Drugs & Pharmacology Authors: Source Type: research

Related Links:

We present a case of a 19-month infant who was taken to the Emergency Department due to fever and a gingival lesion that did not respond to antibiotic treatment. An ultrasound study was requested to assess the presence of an abscess. However, a lesion was identified and after performing a biopsy, pathologist found it was a myeloid sarcoma. The patient was diagnosed with AML and chemotherapy treatment was started. After three cycles of treatment, the patient is currently free of disease.
Source: Revista Espanola de Cirugia Oral y Maxilofacial - Category: ENT & OMF Source Type: research
We present a case of a 19-month infant who was taken to the Emergency Department due to fever and a gingival lesion that did not respond to antibiotic treatment. An ultrasound study was requested to assess the presence of an abscess. However, a lesion was identified and after performing a biopsy, pathologist found it was a myeloid sarcoma. The patient was diagnosed with AML and chemotherapy treatment was started. After three cycles of treatment, the patient is currently free of disease.
Source: Revista Espanola de Cirugia Oral y Maxilofacial - Category: ENT & OMF Source Type: research
CONCLUSION: Automated BM counts on hematology analyzers contributed to the formulation of a SS for the screening discrimination between reactive and MDS BM fluids, which seems to be applicable and informative, regardless of the analyzer used. PMID: 31102331 [PubMed - as supplied by publisher]
Source: International Journal of Laboratory Hematology - Category: Hematology Authors: Tags: Int J Lab Hematol Source Type: research
Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   IDH1 NP_005887.2:p.R132C;   IDH1 NP_005887.2:p.R132G;   IDH1 NP_005887.2:p.R132H;   IDH1 NP_005887.2:p.R132L;   IDH1 NP_005887.2:p.R132S;   IDH2 NP_002159.2:p.R140X;   IDH2 NP_002159.2:p.R172G;   IDH2 NP_002 159.2:p.R172K;   IDH2 NP_002159.2:p.R172M;   IDH2 NP_002159.2:p.R172W;   Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia;   T...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
We report that lenalidomide and pomalidomide have cytotoxic effects on neither AML cells nor BM-MSCs, but they increase the immunosuppressive/immunomodulatory properties of BM-MSCs. When combined with AraC and Idarubicin, IMiDs fail to circumvent BM stroma-mediated resistance of AML cells in vitro and in vivo but induce robust extramedullary mobilization of AML cells. When administered as a single agent, lenalidomide highly mobilizes AML cells, but not healthy CD34+ cells, to peripheral blood (PB) likely through specific downregulation of CXCR4 in AML blasts. Global gene expression profiling supports a migratory/mobilizati...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
In this study, we performed genome analyses of myelodysplastic syndromes among survivors and found that proximally exposed patients had significantly fewer mutations in genes such as TET2 along the DNA methylation pathways, and they had a significantly higher rate of 11q deletions. Among the genes located in the deleted portion of chromosome 11, alterations of ATM were significantly more frequent in proximally exposed group with mutations identified on the remaining allele in two out of five cases. TP53, which is frequently mutated in therapy-related myeloid neoplasms, was equally affected between proximally and distally e...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
Source: Blood - Category: Hematology Authors: Tags: Free Research Articles, BloodWork, Myeloid Neoplasia, Phagocytes, Granulocytes, and Myelopoiesis BLOOD WORK Source Type: research
Authors: Nguyen HD, Zou L, Graubert TA PMID: 31080550 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
AbstractPurpose of ReviewChronic myelomonocytic leukemia (CMML) is a rare and often aggressive myeloid malignancy. Historically, prognostic markers and therapeutic paradigms have been applied from myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPNs). Interest has increased recently in developing tailored approaches for the MDS/MPNoverlap syndrome of CMML.Recent FindingsMultiple prognostic scores have been validated specifically for CMML in the past 5  years. These incorporate somatic mutations, withASXL1 mutations repeatedly correlating with poor prognosis. Accurate prognostication can guide treatmen...
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research
This study shows that the combination of different strategies is pivotal to fine-tune the diagnosis and the clinical management of the patient. After 1 year of treatment with imatinib, the patient achieves hematological and molecular remission. We present an attractive strategy to identify novel and/or cryptic fusions, which will be relevant for clinicians dealing with the diagnosis of the patients with myelodysplastic syndrome/myeloproliferative diseases with atypical manifestations.Acta Haematol
Source: Acta Haematologica - Category: Hematology Source Type: research
More News: Drugs & Pharmacology | Genetics | Myelodysplastic Syndrome